Sabine C Herpertz Selected Research

Borderline Personality Disorder (Personality Disorders, Borderline)

1/2022	Relationship between Borderline Personality Disorder, Emotional Availability, and Cortisol Output in Mother-Child Dyads.
1/2022	Reduced vagal activity in borderline personality disorder is unaffected by intranasal oxytocin administration, but predicted by the interaction between childhood trauma and attachment insecurity.
1/2021	Associations between age and cortisol awakening response in patients with borderline personality disorder.
1/2020	Heart and brain: Cortical representation of cardiac signals is disturbed in borderline personality disorder, but unaffected by oxytocin administration.
1/2020	Oxytocin Normalizes Approach-Avoidance Behavior in Women With Borderline Personality Disorder.
7/2019	[Erratum to: Oxytocin and maltreatment potential : Influence of maternal depression, borderline personality disorder and experience of early childhood maltreatment].
3/2019	[Oxytocin and maltreatment potential : Influence of maternal depression, borderline personality disorder and experience of early childhood maltreatment].
1/2018	Oxytocin and Borderline Personality Disorder.
1/2018	Correlates of Aggression in Personality Disorders: an Update.
11/2017	Divergent effects of oxytocin on (para-)limbic reactivity to emotional and neutral scenes in females with and without borderline personality disorder.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sabine C Herpertz Research Topics

Disease

18	Borderline Personality Disorder (Personality Disorders, Borderline) 01/2022 - 11/2007
6	Hypersensitivity (Allergy) 01/2021 - 10/2013
5	Pain (Aches) 01/2020 - 09/2015
4	Mental Disorders (Mental Disorder) 01/2021 - 10/2013
4	Antisocial Personality Disorder (Antisocial Personality) 01/2018 - 06/2005
3	Personality Disorders (Personality Disorder) 09/2020 - 01/2007
3	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 01/2017 - 05/2008
2	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 09/2022 - 01/2019
2	Low Back Pain (Lumbago) 01/2020 - 01/2020
2	Asperger Syndrome (Asperger's Syndrome) 02/2014 - 08/2013
2	Autism Spectrum Disorder 08/2013 - 03/2007
1	Major Depressive Disorder (Major Depressive Disorders) 09/2022
1	Medically Unexplained Symptoms 09/2022
1	Schizophrenia (Dementia Praecox) 11/2021
1	Wounds and Injuries (Trauma) 01/2020
1	Chronic Pain 01/2020
1	Neurocognitive Disorders (Clerambault Syndrome) 03/2015
1	Insulin Resistance 01/2014
1	Chronic Disease (Chronic Diseases) 11/2011
1	Alzheimer Disease (Alzheimer's Disease) 01/2010
1	Hyperkinesis 12/2008
1	Conduct Disorder (Conduct Disorders) 04/2007

Drug/Important Bio-Agent (IBA)

21	Oxytocin (Pitocin)FDA LinkGeneric 01/2022 - 03/2007
4	Hydrocortisone (Cortisol)FDA LinkGeneric 01/2022 - 05/2015
4	Biological ProductsIBA 01/2021 - 06/2005
4	4-aminospiroperidolIBA 01/2018 - 02/2013
2	NeuropeptidesIBA 01/2020 - 10/2019
2	Methylphenidate (Ritalin)FDA LinkGeneric 01/2017 - 05/2008
2	Biomarkers (Surrogate Marker)IBA 03/2015 - 01/2010
1	Silver Sulfadiazine (SSD)FDA LinkGeneric 09/2022
1	Analgesics (Analgesic Drugs)IBA 01/2020
1	Therapeutic UsesIBA 01/2020
1	Aminobutyrates (Aminobutyric Acid)IBA 01/2018
1	Triiodothyronine (Liothyronine)FDA LinkGeneric 01/2018
1	CannabinoidsIBA 09/2015
1	Testosterone (Sustanon)FDA Link 05/2015
1	Amyloid (Amyloid Fibrils)IBA 03/2015
1	LeptinIBA 01/2014
1	Antidepressive Agents (Antidepressants)IBA 01/2007
1	Pharmaceutical PreparationsIBA 01/2007
1	Psychotropic Drugs (Psychoactive Drugs)IBA 01/2007
1	Antipsychotic Agents (Antipsychotics)IBA 01/2007

Therapy/Procedure

4	Therapeutics 09/2020 - 11/2007
2	Transcranial Magnetic Stimulation 12/2008 - 05/2008
1	Secondary Prevention 11/2021
1	Continuity of Patient Care 11/2021
1	Intranasal Administration 10/2013